Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

European Journal of Clinical Pharmacology

Volumn 62, Issue 6, 2006, Pages 431-436

  Kim, Myong Jin ^a   Nafziger, Anne N ^a,b   Kashuba, Angela D M ^c   Kirchheiner, Julia ^d   Bauer, Steffen ^e   Gaedigk, Andrea ^f   Bertino Jr , Joseph S ^b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Cigarette smoking; CYP2C9; Fluvastatin; S warfarin

Indexed keywords

CYTOCHROME P450 2C9; FLUINDOSTATIN; VITAMIN K GROUP; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; MALE; MOLECULAR PROBE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENOTYPE; HUMANS; INDOLES; MALE; MIDDLE AGED; PHARMACOGENETICS; SMOKING; STEREOISOMERISM; WARFARIN;

EID: 33745037225     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0124-0     Document Type: Article

References (21)

1. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T et al (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59
2. Appel S, Dingemanse J (1996) Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications. Rev Contemp Pharmacother 7:167-182
3. Transon C, Leemann T, Vogt N, Dayer P (1995) In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 58:412-417
4. Brown CR, Jacob P 3rd, Wilson M, Benowitz NL (1988) Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clin Pharmacol Ther 43:488-491
5. Czekaj P, Wiaderkiewicz A, Florek E, Wiaderkiewicz R (2005) Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta. Arch Toxicol 79:13-24
6. Jennings TS, Nafziger AN, Davidson L, Bertino JS Jr (1993) Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med 122:208-216
7. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S et al (2004) PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251-265
8. Rettie AE, Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494
9. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr (2001) Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 41:715-722
10. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E et al (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5 +1 cocktail". Clin Pharmacol Ther 74:437-447
11. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439
12. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
13. Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE (1998) Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl 710:143-148
14. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I et al (2003) Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 74:186-194
15. Williams RL, Chen ML, Hauck WW (2002) Equivalence approaches. Clin Pharmacol Ther 72:229-237
16. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
17. Weiner B, Faraci PA, Fayad R, Swanson L (1984) Warfarin dosage following prosthetic valve replacement: effect of smoking history. Drug Intell Clin Pharm 18:904-906
18. Benowitz NL (1988) Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 319:1318-1330
19. Nakajima M, Kuroiwa Y, Yokoi T (2002) Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 34:865-877
20. Transon C, Leemann T, Dayer P (1996) In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209-215
21. Appel S, Rufenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G et al (1995) Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 76:29A-32A